James Waldron

Apogee Therapeutics has secured a promise of up to $1.3 billion in financing from Blackstone Life Sciences (BXLS) as the biotech gears up to take its anti-IL-13 antibody into phase 3.

Novartis may be launching an array of vehicles to shuttle drugs across the blood-brain barrier, but executives told Fierce that the Swiss pharma is “always looking” for new ways to traverse this final frontier of neuroscience.

Hoth Therapeutics' search for salvation in the stars appears to have been rewarded by investors, as the company's stock doubled after a pivot to powering AI in space.

Gilead has abandoned work on the lead drug from its $405 million buyout of MiroBio in the latest blow to the BTLA agonist field.

Agios Pharmaceuticals' next-gen pyruvate kinase (PK) activator has failed a phase 2 study in a group of rare blood cancers, although the biopharma is still holding out hope in sickle cell disease (SCD).

Eli Lilly has expanded its glucagon-like peptide (GLP) portfolio in an intriguing direction by licensing a phase 2-stage GLP-2 agonist from Hanmi Pharm.

Within hours of securing a gastrointestinal drug from Korea's Hanmi Pharma, Eli Lilly has ramped up the biobucks for a wider-ranging pact with China's Haisco Pharmaceutical.

Days after its lead clinical-stage drug suffered a setback, Agios Pharmaceuticals has rebounded by

Praxis Precision Medicines’ epilepsy pipeline has suffered a setback after a next-gen NaV blocker failed to sufficiently reduce seizures in a phase 2/3 study.

Fulcrum Therapeutics has scrapped its sole clinical-stage program after the FDA took a hard line on the modality following the recent withdrawal of Ipsen's Tazverik from the U.S. market.